MRK

Buying Merck & (MRK)? Here's What You Must Know.

Shares of Merck & have moved -1.4% today, and are now trading at a price of $101.64. In contrast, the S&P 500 index saw a 1.0% change. Today's trading volume is 5,569,888 compared to the stock's average volume of 10,476,368.

Merck & Co., Inc. operates as a healthcare company worldwide. Based in Rahway, United States the company has 70,000 full time employees and a market cap of $260,856,004,608. Merck & currently offers its equity investors a dividend that yields 2.9% per year.

The company is now trading -22.01% away from its average analyst target price of $130.33 per share. The 25 analysts following the stock have set target prices ranging from $100.0 to $155.0, and on average give Merck & a rating of buy.

Over the last 12 months MRK shares have declined by -3.3%, which represents a difference of -35.3% when compared to the S&P 500. The stock's 52 week high is $134.63 per share and its 52 week low is $94.48. With its net margins declining an average -41.4% over the last 6 years, Merck & declining profitability gives us reason to believe its stock price will continue to underwhelm.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 60,115,000 365,000 1 -95.83
2022 59,283,000 14,519,000 24 -11.11
2021 48,704,000 13,049,000 27 58.82
2020 41,518,000 7,067,000 17 -32.0
2019 39,121,000 9,843,000 25 66.67
2018 42,294,000 6,220,000 15
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS